• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Advanced Inhalation Therapies scales back IPO terms to $10m

Advanced Inhalation Therapies scales back IPO terms to $10m

January 12, 2016 By Brad Perriello

Advanced Inhalation TherapiesAdvanced Inhalation Therapies yesterday scaled its pending initial public offering by more than ⅔ as it looks to raise funds for its drug delivery device, which is designed to treat severe respiratory infections and lung diseases using a high dose of nitric oxide.

When it registered for the IPO back in August 2015, Rehovot, Israel-based AIT set the high end of the offering at $36 million. Yesterday the company said it plans to float 675,000 shares at $15 apiece, for gross proceeds of $10.1 million.

Losses for AIT last year widened by 200%, to -$4.6 million, or -41¢ per share, compared with 2013. For the 6 months ended June 30, 2015, however, the company pared its losses by -37.5%, to  -$2 million, or -20¢ per share, compared to the 1st half of 2014.

AIT is developing a device, the NOxSysBS, which is designed to deliver a gaseous, high-dosage blend of NO, oxygen and air. The FDA has only approved a 20 ppm NO vasodilation treatment, which AIT said isn’t effective in treating microbial infections. The NOxSysBS device is designed to deliver 160 ppm of NO, which the body produces on its own to fight infections.

The company, founded in 2011, plans to list on the NASDAQ exchange under the “AITP” symbol. Joseph Gunnar is the offering’s lone  bookrunner, replacing Aegis Capital.

The company said its initial targets are a pair of lower respiratory tract infections, children with bronchitis and lung infections in patients with cystic fibrosis. AIT said it already has a pair of Phase IIa trials under its belt for the initial indications.

“We believe that the results of both trials suggest the safety and efficacy of our product candidates,” the company said in its registration filing. “We have received orphan drug designation by the FDA and the European Medicines Agency for the use of our NOxCF product candidate for the treatment of CF-related lung infections.”

AIT reported that its R&D expenses rose 29.3% to $1.2 million and losses widened 193.6% to -$4.6 million for 2014.

Filed Under: Funding Roundup, Initial Public Offering (IPO), Respiratory Tagged With: Advanced Inhalation Therapies

More recent news

  • Preceptis Medical has a new CEO as it advances ear tube tech
  • FDA clears first over-the-counter cuffless blood pressure monitor
  • Mendaera wins FDA clearance for robotic needle placement
  • Johnson & Johnson seeks to have $442 million antitrust verdict tossed out
  • Former Masimo COO is joining BD to run Connected Care

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy